Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients
SENCOVAC Collaborative Network; Quiroga, Borja; Jose Soler, Maria; Ortiz, Alberto; Martinez Vaquera, Shaira; Jarava Mantecón, Carlos Jesus; Useche, Gustavo; Sanchez Marquez, Maria Gabriela; Carnerero, Manuel; Jaldo Rodriguez, Maria Teresa

Published in:
Nephrology Dialysis Transplantation

DOI:
10.1093/ndt/gfab313

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
SENCOVAC Collaborative Network, Quiroga, B., Jose Soler, M., Ortiz, A., Martinez Vaquera, S., Jarava Mantecón, C. J., Useche, G., Sanchez Marquez, M. G., Carnerero, M., Jaldo Rodriguez, M. T., Munoz Ramos, P., Ruiz San Millan, J. C., Toapanta, N., Gracia-Iguacel, C., Aguilar Cervera, M. C., Balibrea Lara, N., Leyva, A., Rojas, J., Gansevoort, R. T., & de Sequera, P. (2022). Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrology Dialysis Transplantation, 37(10). Advance online publication. https://doi.org/10.1093/ndt/gfab313

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study

Borja Quiroga, María José Soler, Alberto Ortiz, Shaira Martínez Vaquera, Carlos Jesús Jaraua Mantecón, Gustavo Usoche, María Gabriela Sánchez Márquez, Manuel Carnerero, María Teresa Jaldo Rodríguez, Patricia Muñoz Ramos, Juan Carlos Ruiz San Millán, Nestor Toapanta, Carolina Gracia-Iguacel, María Cinta Aguilar Cervera, Noelia Balibrea Lara, Alba Leyva, José Rojas, Ron T. Gansevoort and Patricia de Sequera; SENCOVAC Collaborative Network

1Nephrology Department, Hospital Universitario de la Princesa, Madrid, Spain, 2Nephrology Department, Vall d’Hebron University Hospital, Barcelona, Spain, 3IIS-Fundación Jimenez Díaz, School of Medicine, Universidad Autónoma de Madrid, Fundación Renal Iñigo Alvarez de Toledo-IRSIN, REDinREN, Instituto de Investigación Carlos III, Madrid, Spain, 4Diaverum, Spain, 5Nephrology Department, Hospital Universitario Puerto Real, Cádiz, Spain, 6Nephrology Department, Infanta Leonor University Hospital, Madrid, Spain, 7Nephrology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Nephrology Department, Hospital Universitario Donostia, San Sebastián, Spain, 9Nephrology Department, Hospital General Universitario de Alicante, Alicante, Spain, 10R&D Department, Vircell S.L., Granada, Spain and 11Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Correspondence to: María José Soler; E-mail: mjsoler01@gmail.com; Twitter handle: @PepaSolerR; and Alberto Ortiz; E-mail: aortiz@fjd.es

ABSTRACT

Background. Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here.

Methods. Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed.

Results. A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P < 0.001). In a multivariate adjusted analysis, absence of an antibody response was independently associated with KT (odds ratio 20.56, P = 0.001) and with BNT162b2 vaccine (odds ratio 6.03, P = 0.023).

Conclusion. The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.

Keywords: antibodies, COVID-19, humoral response, SARS-CoV-2, vaccine

INTRODUCTION

Coronavirus disease 2019 (COVID-19) has caused millions of deaths worldwide, being especially lethal in vulnerable populations, such as patients with chronic kidney disease (CKD), those on dialysis and kidney transplant (KT) recipients [1]. Dialysis, organ transplantation and CKD patients with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² represent three of the four comorbidities associated with the highest mortality risk from COVID-19 [2]. Several circumstances exacerbate the impact of severe acute
KEY LEARNING POINTS

What is already known about the subject?
- Coronavirus disease 2019 (COVID-19) has caused millions of deaths worldwide, being especially lethal in vulnerable populations, such as chronic kidney disease (CKD), dialysis and kidney transplant (KT) patients.
- Dialysis, organ transplantation and CKD patients with estimated glomerular filtration rate <30 mL/min/1.73 m² represent three of the four comorbidities associated with the highest mortality risk from COVID-19.
- Low seroconversion rate to mRNA vaccines has been preliminarily reported in KT patients.

What this study adds?
- SENCOVAC demonstrated the safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in peritoneal dialysis, haemodialysis, KT and non-dialysis CKD patients.
- Vaccination with mRNA-1273 (Moderna) resulted in better serological response than vaccination with BNT162b2 (Pfizer-BioNTech) in KT recipients and other CKD populations.
- Absence of antibody response was independently associated with KT (odds ratio 20.56) and BNT162b2 vaccination (odds ratio 6.03).

What impact this may have on practice or policy?
- Isolation measures should be maintained in CKD patients, especially in KT recipients, at high-risk of COVID-19.
- KT patients may benefit from a booster dose of a COVID-19 vaccine, as some authorities are now recommending.
- CKD patients at high-risk for SARS-CoV-2 infection should be monitored, even if they are asymptomatic, as 50% of them could be reinfected by SARS-CoV-2.

respiratory syndrome coronavirus 2 (SARS-CoV-2) on the morbidity and mortality of CKD patients. Beyond the inherent immunosuppression secondary to impaired renal function [3], haemodialysis (HD) and KT patients present specific characteristics, such as immunosuppressive therapy and comorbidities, that enhance their risk for developing severe COVID-19.

The fast development and approval of SARS-CoV-2 vaccines has decreased the severity of the COVID-19 pandemic in countries with high immunization rates. However, there is concern regarding the humoral response of CKD patients to vaccination against SARS-CoV-2. Data on KT patients are the most worrisome, with a seroconversion rate lower than 50% in the majority of published studies [4]. In addition, recent series have shown limited development of anti-Spike antibodies, even after three vaccine doses [5]. In contrast, preliminary studies suggest that HD patients reach higher anti-Spike antibody levels after the administration of mRNA vaccines than KT patients, but lower than the general population [6]. Two recent reports involving peritoneal dialysis (PD) patients suggest that this population acquires similar humoral and cellular responses to HD patients, at least in the short term [7, 8]. Regarding non-dialysis CKD patients, available data are limited as those patients are systematically excluded from clinical trials, and to our knowledge no specific studies have been published to date [9].

Despite the heterogeneous available data, a correct understanding of the efficiency and safety of SARS-CoV-2 vaccines in different populations of CKD patients with different immunological and comorbid backgrounds is a priority for delineating further actions according to their specific susceptibility and response to COVID-19 vaccination.

The aim of the multicentric SENCOVAC study was to evaluate the humoral response and safety of the SARS-CoV-2 vaccines in CKD patients, comparing the humoral response in four different cohorts: PD, HD, KT and non-dialysis CKD patients. We now present the SENCOVAC study results in terms of adverse events (AE) and the preliminary report on the immediate humoral response as assessed by the antibody response 28 days after complete COVID-19 vaccination.

MATERIALS AND METHODS

Study design
SENCOVAC is a Spanish Society of Nephrology prospective and multicentric study including four cohorts of adult patients with CKD: KT recipients, HD, PD and non-dialysis CKD patients (stages 4 and 5, eGFR <30 mL/min/1.73 m²). All the screened participants received the complete immunization schedule with any of the available vaccines: BNT162b2 (Pfizer-BioNTech®), mRNA-1273 (Moderna®), ChAdOx1-S (AstraZeneca®) or Ad26.COV.2 (Janssen®) as per local public health authorities’ prescription at their respective Autonomous Communities during routine clinical care.

Patients
Fifty centres in Spain participated in the study. Out of the 1930 screened patients, 1746 were included (Figure 1). Inclusion criteria were age older than 18 years, capability of understanding the purpose and risks of the study, fully informed written consent and a diagnosis of CKD as KT recipients, HD, PD or non-dialysis CKD with eGFR <30 mL/min/1.73 m². Exclusion criteria were contraindication for vaccination, solid organ transplantation different from kidney, active oncolgical or haematological disease, primary immunodeficiency disease, human immunodeficiency virus and immunosuppressive treatment 6 months before vaccination for non-KT recipients.

Objectives
The primary objective was to determine the rates of anti-SARS-CoV-2 Spike antibody development in CKD patients. Anti-Spike antibodies correlate with neutralizing activity
FIGURE 1: Participant flow chart. The humoral response evaluation population represents the first 301 patients with anti-Spike antibody results at 28 days after completing the vaccination schedule. Ab, antibodies.

[10]. Secondary objectives included safety (immediate local and systemic reactions and other AE) and effectiveness at preventing further SARS-CoV-2 infection.

Variables and outcomes
In this interim analysis, we assessed safety and the humoral response at 28 days after completion of the vaccination schedule. Patients were studied at baseline, after the administration of the vaccine doses and at 28 days. At baseline, investigators registered epidemiological data, comorbidities [including previous COVID-19 infection (defined by the investigator with a positive antigen or polymerase chain reaction against SARS-CoV-2)], long-term treatments, vital signs and laboratory values. In addition, each cohort had specific registries based on the kidney situation (Kt/V, dialysis vintage, technique and vascular access for HD and PD patients; immunosuppressive therapy for KT).

Antibody testing
At baseline and at 28 days, a 2-mL serum sample was obtained and sent to a central laboratory for antibody determinations. All samples were tested by a CE-marked commercial method, a quantitative chemiluminescence immunoassay (CLIA, COVID-19 Spike Quantitative Virclia® IgG Monotest, Vircell S.L., Spain), with a sensitivity and specificity of 96% and 100%, respectively, which detects IgG antibodies against the SARS-CoV-2 Spike protein. This assay was calibrated against the First World Health Organization International Standard for anti-SARS-CoV-2 human immunoglobulin (NIBSC code: 20/136) and results were expressed as IU/mL. According to the performance studies of the manufacturer, based on the analysis of prepandemic serum samples, values \( \leq 32 \) IU/mL were considered as negative, between 32 and 36 IU/mL as equivocal and values \( >36 \) IU/mL as positive, reflecting the presence of anti-Spike IgG antibodies as a consequence of either previous infection or vaccination.

Adverse events and vaccine reactions
After each vaccine dose, patients were asked to complete the AE questionnaire.
During the study all patients were followed, and any AE was registered. Serious AE were considered if they led to death, were life-threatening, needed hospitalization or caused disability, as considered by the investigators.

Ethical concerns
The study was approved by the Ethical Committee of Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz in February 2021.
Table 1. Baseline characteristics of participants

|                        | Total (n = 1746) | KT (n = 283) | PD (n = 171) | HD (n = 1116) | CKD (n = 176) | P     |
|------------------------|------------------|-------------|-------------|---------------|---------------|-------|
| **Sex (male), n (%)**  | 1092 (62)        | 171 (60)    | 100 (58)    | 719 (64)      | 102 (58)      | 0.170 |
| **Age (years)**        | 64 (13)          | 56 (13)     | 60 (14)     | 65 (12)       | 64 (14)       | <0.001|
| **Diabetic kidney disease, n (%)** | 369 (22)    | 10 (4)      | 37 (22)     | 280 (25)      | 42 (26)       | <0.001|
| **Haemodialysis technique, n (%)** | —           | —           | —           | —             | —             | —     |
| HFHD                   | 486 (44)         | —           | —           | 486 (44)      | —             | —     |
| HDx                   | 39 (3)           | —           | 39 (3)      | —             | —             | —     |
| OL-HDF                | 589 (53)         | —           | —           | 589 (53)      | —             | —     |
| **Vascular access, n (%)** | —           | —           | —           | —             | —             | —     |
| AVF                   | 696 (64)         | —           | —           | 696 (64)      | —             | —     |
| Catheter              | 394 (36)         | —           | —           | 394 (36)      | —             | —     |
| **Immunosuppression, n (%)** | —           | —           | —           | —             | —             | —     |
| Steroids              | 182 (64)         | 182 (64)    | —           | —             | —             | —     |
| Calcineurin inhibitors | 216 (73)         | 216 (73)    | —           | —             | —             | —     |
| Mycophenolate mofetil  | 200 (71)         | 200 (71)    | —           | —             | —             | —     |
| mTORi                 | 46 (16)          | 46 (16)     | —           | —             | —             | —     |
| Azathioprine           | 9 (3)            | 9 (3)       | —           | —             | —             | —     |
| **Anticoagulants, n (%)** | 270 (15)    | 23 (8)      | 28 (16)     | 28 (16)       | 29 (16)       | 0.003 |
| Antiplatelet agents    | 627 (36)         | 76 (27)     | 56 (31)     | 435 (39)      | 63 (36)       | 0.001 |
| **RAASi, n (%)**       | 584 (33)         | 128 (45)    | 89 (52)     | 300 (27)      | 67 (38)       | <0.001|
| **ESA, n (%)**         | 1105 (63)        | 42 (15)     | 111 (65)    | 853 (77)      | 99 (56)       | <0.001|
| **Vaccine, n (%)**     | —                | —           | —           | —             | —             | —     |
| BNT162b2              | 511 (29)         | 54 (19)     | 28 (16)     | 190 (17)      | 29 (16)       | 0.003 |
| mRNA-1273             | 1202 (69)        | 225 (79)    | 89 (52)     | 300 (27)      | 67 (38)       | <0.001|
| ChAdOx1-S             | 25 (1)           | 4 (1)       | 3 (2)       | 15 (1)        | 3 (2)         | —     |
| Ad26.COV2             | 8 (1)            | 0 (0)       | 4 (2)       | 4 (2)         | —             | —     |
| **Previous COVID-19, n (%)** | 162 (9)    | 17 (6)      | 20 (12)     | 117 (10)      | 8 (4)         | 0.051 |
| **Baseline anti-Spike Ab+, n (%)** | 69 (23)    | 13 (30)     | 11 (21)     | 37 (21)       | 8 (29)        | 0.124 |
| Haemoglobin (g/dL)     | 11.6 (10.7–12.6) | 13.3 (11.9–14.7) | 11.4 (10.6–12.4) | 11.3 (10.5–12.2) | 11.6 (10.7–12.4) | 0.002 |
| Leucocyte (10³/mm³)    | 6.3 (5.3–8.0)    | 6.9 (5.6–8.9) | 6.8 (5.5–8.0) | 6.0 (4.9–7.7) | 7.0 (6.1–10.7) | <0.001|
| Lymphocytes (10³/mm³)  | 1.3 (1.0–1.8)    | 1.8 (1.3–2.6) | 1.4 (1.0–1.8) | 1.3 (0.9–1.9) | 1.6 (1.2–2.7) | <0.001|
| Albumin (g/dL)         | 3.9 (3.6–4.5)    | 4.2 (3.9–4.5) | 3.6 (3.3–3.9) | 3.9 (3.6–4.1) | 4.0 (3.6–4.3) | <0.001|
| Prealbumin (mg/dL)     | 27 (22–32)       | 27 (21–33)  | 30 (26–36)  | 26 (22–30)    | 28 (22–34)    | <0.001|
| C-reactive protein (mg/L) | 0.5 (0.2–1.5) | 1.1 (0.3–3.8) | 1.1 (0.3–3.2) | 3.9 (1.0–10.3) | 1.0 (0.2–3.0) | 0.006 |
| eGFR (mL/min/1.73 m²)  | 36 (14–62)       | 49 (35–66)  | —           | —             | 13 (9–21)     | <0.001^a|
| Influenza vaccine, n (%) | 1274 (73)   | 218 (77)    | 117 (68)    | 831 (75)      | 108 (61)      | 0.001 |
| Anti-HBs, n (%)        | 710 (64)         | 40 (33)     | 83 (77)     | 524 (67)      | 63 (59)       | <0.001|

Data are presented as mean (standard deviation) or median (interquartile range [IQR]) depending on the variable distribution (tested with the Shapiro–Wilk test). Categorical variables were compared using Fisher’s test and continuous variables with t-test or Mann–Whitney, according to the variable distribution. For comparison of continuous variables from more than two groups, analysis of variance or Kruskal–Wallis tests were used. Correlations were calculated using the Spearman test. The statistical analysis was performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Plots were drawn using GraphPad Prism version 9.02 (Graphpad Holdings, LLC).

**Statistical methods**

Data are displayed as mean (standard deviation) or median [interquartile range (IQR)] depending on the variable distribution (tested with the Shapiro–Wilk test). Categorical variables were compared using Fisher’s test and continuous variables with t-test or Mann–Whitney, according to the variable distribution. For comparison of continuous variables from more than two groups, analysis of variance or Kruskal–Wallis tests were used. Correlations were calculated using the Spearman test. The statistical analysis was performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Plots were drawn using GraphPad Prism version 9.02 (Graphpad Holdings, LLC).

**RESULTS**

**Baseline characteristics**

Among the 1746 participants in SENCOVAC, 1092 (62.5%) were male and the mean age was 63.67 ± 13.28 years (Table 1). Vaccine distribution was as follows: 1202 patients (69%) received mRNA-1273, 511 (29%) BNT162b2, 25 (1%) AstraZeneca and 8 (0.5%) Janssen vaccines. As shown in Figure 1, 1116 (64%) patients were on HD, 283 (16%) were KT patients, 176 (10%) were non-dialysis CKD patients and 171 (10%) were on PD. The distribution of the different types of vaccines differed between groups (Table 1). KT recipients, and HD and PD patients were more likely to receive mRNA-1273, and non-dialysis CKD patients BNT162b2 (P < 0.001).

**Local and systemic reactions after vaccination**

The adverse reactions form after the first dose was completed by 1426 participants. Among them, 763 (53.5%) patients developed at least one reaction. Reactions were more frequent in KT recipients, followed by PD and HD patients.

---

*Data are presented as mean (standard deviation) or median [IQR]. HFHD, high flux haemodialysis; HDx, expanded haemodialysis therapy; OL-HDF, online haemodiafiltration; AVF, arteriovenous fistulae; mTORi, mammalian target of rapamycin inhibitors; RAASi, renin–angiotensin–aldosterone inhibitors; Ab, antibodies.

^aE/GFR difference between KT and non-dialysis CKD.*
Table 2. Baseline characteristics regarding the type of mRNA vaccine in safety and humoral response evaluation population

|                          | Safety population | Humoral response evaluation population |
|--------------------------|-------------------|----------------------------------------|
|                          | BNT162b2 (n = 511) | mRNA-1273 (n = 1202)                  | P-value | BNT162b2 (n = 65) | mRNA-1273 (n = 236) | P-value |
| Sex (male), n (%)        | 315 (62)          | 755 (63)                               | 0.041   | 45 (69)          | 165 (70)          | 0.915   |
| Age (years), mean (SD)   | 68 (13)           | 60 (13)                                | <0.001  | 65 (15)          | 61 (12)           | 0.018   |
| Diabetic kidney disease, n (%) | 113 (23)       | 246 (22)                               | 0.495   | 12 (18)          | 61 (27)           | 0.349   |
| Haemodialysis technique, n (%) | <0.001        |                                        |         | 0.931            |                  |        |
|                        | HFHD             | 103 (31)                               | 375 (49) | 7 (21)          | 34 (24)           |         |
|                        | HDx              | 15 (5)                                 | 24 (3)   | 1 (3)           | 4 (3)             |         |
|                        | OL-HDF           | 212 (64)                               | 366 (48) | 26 (76)         | 106 (74)          |         |
| Vascular access, n (%)  |                  |                                        | 0.310   |                  |                  | 0.681   |
|                        | AVF              | 197 (60)                               | 487 (66) | 20 (59)         | 78 (55)           |         |
|                        | Catheter         | 132 (40)                               | 255 (34) | 14 (41)         | 64 (45)           |         |
| Immunosuppression, n (%) |                  |                                        |         |                  |                  | 0.002   |
| Steroids                | 41 (8)           | 217 (18)                               | <0.001  | 13 (20)         | 37 (16)           | 0.407   |
| Calcineurin inhibitors   | 42 (8)           | 188 (16)                               | <0.001  | 13 (20)         | 27 (11)           | 0.097   |
| Mycophenolate mofetil    | 38 (7)           | 173 (14)                               | 0.001   | 11 (17)         | 29 (12)           | 0.311   |
| mTORi                   | 9 (2)            | 38 (3)                                 | 0.306   | 1 (1)           | 5 (2)             | 1.000   |
| Azathioprine             | 2 (0)            | 9 (1)                                  | 0.815   | 1 (1)           | 2 (1)             | 0.519   |
| Anticoagulants, n (%)    | 91 (18)          | 178 (15)                               | 0.089   | 17 (26)         | 34 (14)           | 0.038   |
| Antiplatelet agents, n (%)| 188 (37)      | 425 (35)                               | 0.789   | 26 (40)         | 83 (35)           | 0.471   |
| RAASi, n (%)             | 156 (30)         | 416 (35)                               | 0.109   | 23 (35)         | 109 (46)          | 0.158   |
| ESA, n (%)               | 354 (69)         | 729 (61)                               | 0.003   | 41 (63)         | 160 (68)          | 0.552   |
| CKD cohort, n (%)        |                  |                                        | <0.001  |                  |                  | 0.002   |
| KT                       | 54 (11)          | 225 (19)                               |         | 12 (18)         | 31 (13)           |         |
| PD                       | 26 (5)           | 142 (12)                               |         | 6 (9)           | 46 (19)           |         |
| HD                       | 331 (65)         | 766 (64)                               |         | 34 (52)         | 144 (61)          |         |
| CKD                      | 100 (20)         | 69 (6)                                 |         | 13 (20)         | 15 (6)            |         |
| Previous COVID-19, n (%) | 33 (6)           | 127 (11)                               | 0.037   | 2 (3)           | 51 (22)           | 0.001   |
| Baseline anti-Spike Ab+, n (%) |            |                                        |         | 12 (18)         | 57 (24)           | 0.585   |
| Influenza vaccine, n (%) | 349 (68)         | 901 (75)                               | 0.011   | 54 (83)         | 165 (70)          | 0.041   |
| Anti-HBs, n (%)          | 229 (63)         | 465 (64)                               | 0.612   | 36 (64)         | 120 (60)          | 0.856   |

Safety population included patients included in the study. Humoral response evaluation population included patients with tested anti-Spike antibodies.

HFHD, high flux haemodialysis; HDx, expanded haemodialysis therapy; OL-HDF, online haemodiafiltration; AVF, arteriovenous fistulae; mTORi, mammalian target of rapamycin inhibitors; RAASi, renin–angiotensin–aldosterone inhibitors; Ab, antibodies.

(P < 0.001) (Supplementary data, Figure S1). Vaccine reactions were more frequent in younger patients (P < 0.001 for all groups combined, not shown). Specifically, vaccine reactions were more frequent in younger KT recipients (P = 0.016) and in younger persons with non-dialysis CKD (P = 0.012) than in older participants from these groups (not shown). Previous COVID-19 infection was also associated with higher rates of reactions after the first dose (64% versus 53%) (P = 0.038). The most frequent reaction was local pain (506, 73%) followed by general discomfort (163, 22%) and asthenia (160, 21%) (Supplementary data, Table S2). mRNA-1273 vaccine was associated with higher rates of local pain, erythema, swelling, skin hypersensitivity, low-grade fever and fever, headache, asthenia, chills and general discomfort. Among patients who were working, those who had received mRNA-1273 requested a work leave more frequently (P = 0.015).

The adverse reactions form after the second dose was completed by 1359 patients. Among them, 741 (54.5%) developed at least one reaction. Reactions were more frequent in KT patients (P = 0.006) (Supplementary data, Figure S1). Vaccine reactions to the second dose were also more frequent in younger patients (P < 0.001 for all groups combined, not shown). Specifically, vaccine reactions were more frequent in younger KT patients (P = 0.035) and in younger non-dialysis CKD patients (P = 0.003) than in older participants from these groups (not shown). Previous COVID-19 infection was also associated with higher rates of reactions after the second dose (65% versus 53%) (P < 0.001). The most frequent reaction was local pain (493, 68%) followed by general discomfort (261, 36%) and asthenia (258, 36%) (Supplementary data, Table S3). The second dose of mRNA-1273 produced more frequent local pain, erythema, swelling, itching, skin hypersensitivity, low-grade fever and fever, headache, asthenia, myalgia, chills, general discomfort and arthralgias than the other vaccines. Among patients who were working, those who had received mRNA-1273 asked for a work leave more frequently (P = 0.002).

**Anti-Spike antibodies**

Development of anti-Spike antibodies 28 days after completing vaccination has been tested in 301 patients (28 non-dialysis CKD patients, 43 KT recipients, 52 PD and 178 HD patients). Baseline characteristics for these patients are presented in Supplementary data, Table S4. At baseline, 69 patients (23%) presented anti-Spike antibodies, 6 (2%) had an equivocal result and 226 (75%) had no anti-Spike antibodies. Among patients with baseline anti-Spike antibodies, 35 (51%) had a known history of COVID-19.
Twenty-eight days after completing vaccination, 289 patients (95%) presented anti-Spike antibodies, 2 (1%) were equivocal and 14 (5%) had a negative result. Patients that did not develop anti-Spike antibodies post-vaccination included nine (21%) KT recipients, four (2%) HD patients and one (1%) PD patient (P < 0.001) (Supplementary data, Figure S2).

Among the 226 patients that did not have anti-Spike antibodies at baseline, the rate of de novo antibody development was 94% for all groups combined. Among these patients, 170 (98%) of patients receiving mRNA-1273 developed anti-Spike antibodies as compared with 42 (81%) patients receiving BNT162b2 (P < 0.001). Specifically, among patients without anti-Spike antibodies at baseline, 12 (5.3%) did not develop a humoral response. Patients who did not develop de novo antibodies included seven (26%) of the KT recipients, one (2%) PD patients and four (3%) HD patients (P < 0.001) (Supplementary data, Figure S3).

Interestingly, in two patients who had positive or equivocal anti-Spike antibodies at baseline, these were not observed 28 days following vaccination. These two patients belonged to the KT group, displayed very low baseline anti-Spike antibody titres (34 and 42 IU/mL) and received mRNA-1273 and BNT162b2 vaccines, respectively. Among KT patients with a history of COVID-19, 100% had antibodies after vaccination.

As shown in Figure 2, in the overall analysis, KT recipients presented lower titres of anti-Spike antibodies than HD (P = 0.001), PD (P < 0.001) and non-dialysis CKD (P = 0.002) patients. When the analysis was restricted to patients without anti-Spike antibodies at baseline, similar results were obtained: KT was the group with lower de novo antibody generation (P = 0.011 versus HD; P < 0.001 versus PD; and P = 0.013 versus CKD) (Supplementary data, Figure S4).

Focusing specifically on KT recipients without baseline anti-Spike antibodies, anti-Spike antibodies developed in 14 (82%) of those receiving mRNA-1273 and in 6 (60%) of those receiving BNT162b2 vaccines (P = 0.365).

Factors associated to the development of anti-Spike antibodies

Among patients in whom antibodies were assessed, 53 had a history of COVID-19. Of these, 35 (66%) patients had anti-Spike antibodies at baseline [4 (80%) of KT recipients with prior COVID-19, 5 (50%) of PD, 25 (68%) of HD and 1 (100%) of non-dialysis CKD patients (P = 0.249)].

Previous COVID-19 infection was associated with higher anti-Spike titres at 28 days [median 10 000 (IQR 5722–10 000) IU/mL versus 3529 (IQR 661–10 000); P < 0.001]. Within specific groups, these differences were significant in KT recipients and in HD patients (Figure 3). Patients with baseline positive anti-Spike antibodies also presented higher anti-Spike antibody titres at 28 days [median 10 000 (IQR 2686–10 000) IU/mL versus 2928 (IQR 655–10 000); P < 0.001] (Supplementary data, Figure S5).

Patients receiving mRNA-1273 developed higher anti-Spike titres [median 10 000 (IQR 1716–10 000) IU/mL] than those receiving BNT162b2 [median 964 (IQR 109–4213) IU/mL] (P < 0.0001). These differences were significant in KT, PD and HD patients (Figure 4). Restricting the analysis to those with negative baseline anti-Spike antibodies, mRNA-1273 was superior in developing antibodies in KT, HD and CKD patients (Supplementary data, Figure S6). A mild but significant indirect correlation was observed between age and anti-Spike
titres in both the whole sample and in those patients without baseline anti-Spike antibodies (Supplementary data, Figures S7 and S8). PD patients who had not received previously the seasonal influenza vaccine developed significantly higher anti-Spike titres at 28 days [median 4528 (IQR 1319–10 000) IU/mL versus 10 000 (IQR 5359–10 000); P = 0.029]. However, an adjusted linear regression by age and previous COVID-19 did not show any independent association between influenza vaccine and anti-Spike titres. No differences were found in anti-Spike antibodies titres between patients with or without anti-hepatitis B surface (anti-HBs) antibodies.

A multivariate analysis adjusted for age, baseline anti-Spike antibodies, gender and seasonal influenza vaccine, showed that KT [odds ratio 20.56 (95% confidence interval 3.24–130.45); P = 0.001] and BNT162b2 vaccine [odds ratio 6.03 (95% confidence interval 1.28–28.23); P = 0.023] were independent predictors for the lack of development of anti-Spike antibodies (Table 3).

**DISCUSSION**

The main findings of the interim analysis of the multicentric SENCOVAC study are the safety of current vaccination schedules for patients with advanced CKD and the poor serological response of KT in comparison with HD, PD and non-dialysis CKD patients. Due to the lack of a complete immunological response against SARS-CoV-2, KT recipients are candidates for an early third dose of the vaccine in some countries [5]. Our results demonstrated a suboptimal humoral response in KT recipients even in a very short-term assessment, only 28 days from the completion of the full vaccination schedule. In contrast to the other groups, more than 20% of KT patients did not develop anti-Spike antibodies. Moreover, loss of anti-Spike antibodies following vaccination was documented in at least one of KT recipients who had anti-Spike antibodies at baseline. Our study results agree with preliminary publications strongly suggesting that KT patients are at high risk of COVID-19 infection despite the complete two-dose vaccination schedule [11–13]. Our results also provide hypothesis-generating information on how to optimize seroconversion and anti-Spike antibody titres in advanced CKD patients, as the mRNA-1273 vaccine performed better from the antibody generation point of view than BNT162b2 in this population. These findings may be the basis for prospective randomized controlled studies in CKD patients, but especially, due to their enhanced risk for a suboptimal humoral response, in KT recipients. In this regard, although the study was observational, the administration of mRNA-1273 or BNT162b2 was a random choice by health authorities dependent on vaccine-type availability in different Spanish regional health systems at the time that each regional system decided to vaccinate persons with CKD based on different sequential criteria (advanced age, healthcare personnel and

None of the post-vaccination SARS-CoV-2 infections was lethal.
An important issue not addressed is the link between immune response and efficacy. This last term refers to the possibility of preventing SARS-CoV-2 infection, and even severe disease, hospitalization and deaths after vaccination [14]. Although the relationship between neutralizing antibodies and breakthrough infections has been confirmed in healthy persons, this should be conformed in vulnerable populations [15].

Immunosuppression, age and previous COVID-19 infection influence the development of anti-SARS-CoV-2 antibodies [4, 16]. Surprisingly, in our study age did not predict the strength of the humoral response. This may in part be explained by the lower age in KT recipients and in patients receiving mRNA-1273 [17]. Interestingly, our data show that the type of vaccine was an independent predictor for humoral response. Indeed, mRNA-1273 was associated with higher rates of early anti-Spike antibodies. mRNA-1273 was also associated with more frequent vaccine reactions in this population, which may be interpreted as consistent with a more vigorous immune response. In this regard, a recent network study including maintenance HD patients demonstrated higher protection from SARS-CoV-2 infections with mRNA-1273 in comparison with BNT162b2. In that study, the authors hypothesized about the difficulties of handling BNT162b2 vaccine and its impact on the thermostability, which could decrease effectiveness [12]. However, one of the most feasible reasons for these differences (in terms of adverse reactions and development of humoral response) might be the higher mRNA dose of mRNA-1273 (100 μg versus 30 μg in BNT162b2) [18]. Indeed, a higher dose of hepatitis B virus vaccine is recommended for patients with advanced CKD in order to optimize the immunological response. As the number of breakthrough SARS-CoV-2 infections was low, we cannot yet provide information of the impact of different vaccines on the occurrence of COVID-19 in advanced CKD patients. In this regard, in some vulnerable cohorts BNT162b2 has been suggested to limit the risk of vigorous vaccine reactions.

To our knowledge, our study is the first to also analyse non-dialysis CKD patients in comparison with patients on kidney replacement therapy. Interestingly, and despite the low eGFR of this subgroup, they displayed a very high rate of humoral response after completing the full vaccination schedule. Although uraemia alters humoral immunity, our data suggest that, at least in the short-term, non-dialysis CKD patients have higher seroconversion rates than CKD patients on kidney replacement therapy [19]. As previously demonstrated, PD and HD patients also reached high rates of seroconversion [4]. Interestingly, the stratified analysis according to previous SARS-CoV-2 exposure shows differences in antibody production in the different subgroups. Specifically, HD patients and KT recipients without prior SARS-CoV-2 infection developed significantly lower anti-Spike antibody responses, suggesting higher risk for post-vaccine COVID-19 infection [20]. Indeed, asymptomatic SARS-CoV-2 infections seem to be an important trigger for higher humoral response to vaccines. Thus, around 50% of participants with baseline anti-Spike antibodies lacked a history of diagnosed COVID-19. This important rate of asymptomatic COVID-19 should alert about the need for maintaining monitoring and mitigation strategies among high-risk populations with impaired immunological response to vaccines. Our results showed that PD, KT and HD patients with anti-Spike antibodies at baseline developed higher antibody titres after vaccination. In concordance, in healthcare professionals, stronger vaccine responses were observed in individuals with prior COVID-19 [21]. However, our study also documented that around 33% of participants with a prior diagnosis of COVID-19 had no anti-Spike antibodies at the time of vaccination. We interpret this as a warning sign of waning of the immune response against SARS-CoV-2 in advanced CKD patients over a relatively short period of time (<15 months).

Serious AE that investigators considered related to the COVID-19 vaccine were registered in two patients. Both were cardiovascular events, one stroke and one myocardial infarction. Although cardiovascular events have been described after SARS-CoV-2 vaccination, the potential causality is unclear, given the high risk of cardiovascular events in CKD patients [22].

Some limitations should be acknowledged. First, the small sample size of patients with measured anti-Spike antibodies, as at the planned interim analyses antibody results were available for 301 patients. This has prevented a subanalysis on the impact of factors such as dialysis efficacy. However, the information obtained is clinically relevant regarding short-term serological responses. These results are of special interest for developing a ‘nephrologist’ common strategy in the recommendation of booster doses of vaccines, mainly to KT recipients. In this regard, the similarity of immunosuppressive regimens for KT recipients precluded the analysis of the impact of different treatment schedules on humoral responses. Second, cellular immunity was not assessed. However, assessment of cellular immunity is unlikely to be available in routine clinical care in the near future. Thus, assessing antibody responses may provide more clinically relevant information. Third, in this first report of the SENCOVAC study, follow-up was short. This may condition the evaluation of the immediate humoral response in patients with delayed seroconversion (such as HD patients) [23]. Additionally, the dose and interval between doses of both mRNA vaccines is different, and this may impact on the dynamics of antibody development. Finally, this was an observational study. However, the choice of vaccine type was randomly dependent on availability of specific vaccine types for different regions, and decided by public health officials unrelated to study participants.

In conclusion, SENCOVAC demonstrates that HD, PD and non-dialysis CKD patients develop a robust early humoral response after SARS-CoV-2 vaccine, especially if they had previous COVID-19. In contrast, KT patients present lower rates of seroconversion and anti-Spike antibody titres at 28 days, suggesting that they may benefit from higher isolation.
measures and booster doses of vaccines. Other CKD patients may benefit from individual monitoring (including assessment of antibody titres) to assess the need for a booster dose if these are not provided to all high-risk individuals by the local health system. Safety and tolerability are acceptable in all the studied CKD cohorts. Hypothesis-generating data suggest a stronger immune response to mRNA-1273 vaccines in advanced CKD patients that should be confirmed in prospective studies and longer-term follow-up of the present cohort. This information would be especially relevant for vaccination and booster vaccines for KT recipients.

**SUPPLEMENTARY DATA**

Supplementary data are available at *ndt* online.

**ACKNOWLEDGEMENTS**

We want to thank all the involved centres and healthcare workers, especially the nurse team, for their implication in this project. In addition, we want to thank the received support of the Sociedad Española de Enfermería Nefrológica (SEDEN), Organización Nacional de Trasplantes (ONT) and Sociedad Española de Trasplante (SET).

**FUNDING**

The present project has been supported by Fresenius Medical Care, Diaverum, Vifor Pharma, Vircell and Fundación Renal Iñigo Álvarez de Toledo.

**CONFLICT OF INTEREST STATEMENT**

M.J.S. reports honorarium for conferences, consulting fees and advisory boards from AstraZeneca, NovoNordisk, Esteve, Vifor, Bayer, Mundipharma, Ingelheim Lilly, Jansen, ICU Medical, and Boehringer. B.Q. has received honoraria for conferences, consulting fees and advisory boards from Vifor-Pharma, Astellas, Amgen, Bial, Ferrer, Novartis, AstraZeneca, Sandoz, Laboratorios Bial, Esteve, Sanofi-Genzyme, Otsuka. A.O. has received consultancy or speaker fees or travel support from Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Otsuka and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra Mundipharma-UMA of diabetic kidney disease and the Catedra AstraZeneca-UMA of chronic kidney disease and electrolytes. C.J.J.M. has received honoraria for one conference from Vifor-Pharma. P.S. reports honorarium for conferences, consulting fees and advisory boards from Amgen, Astellas, Astra Zeneca, Baxter, Braun, Fresenius, Nipro and Vifor-Pharma. S.M.V, G.U., M.G.S.M., M.C., M.T.J.R., P.M.R., J.C.R.S., N.T., C.G., M.C.A.C., N.B.L., A.L., J.R. and R.T.G. do not present conflict of interests.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding authors, M.J.S and A.O., upon reasonable request.

**APPENDIX**

**SENSOCVAC Collaborative Network:**

**Diaverum Andalucia:** José Luis Pizarro León, Manuel Antonio Martínez García, Benaldina García Jiménez, Virginia Olinda Gómez Pérez, Juan de Dios Ramiro Moya, Diana López Espinosa, Alejandro Jiménez Herrador, Manuel Navarro Zurita, Leonardo Díaz Álvarez, Álvaro González Martínez, Sandra Baez Arroyo, Raquel Reina Fernández, Marlyn Janella Suárez Vargas, Rocio Calurano Casero

**Diaverum Valencia:** Amparo Bernat García, Ana Beatriz Muñoz Díaz, Carmen Santamaría de Miguel, Ángel Palacios, Brenda Henningsmeyer, Esther Otero Calve, José Lacueva Moya, Yurika Sato, Marta Serra Marin

**Hospital Universitario Puerto Real:** Carolina Lancho Novillo, Pedro Luis Quiroés Ganga, Fernando Vallejo Carrión, Antonio Luis García Herrera

**Diaverum Murcia-Alicante:** Irene Torres, Pablo Delgado Conde, Georgina Alfaro, Olga Halauko, Fouad El Rifai, Ana Dolores Martínez

**Hospital Universitario Infanta Leonor:** Rafael Lucena Valverde, Marta Puerta Carretero, Mayra Ortega Díaz, Daniel Gaitán Tocora, Esther Rodriguez Suárez, Alfredo José Sáenz Santolaya

**FMC Madrid-Dialcentro:** Sandra Castellano Gash, Lara Ruiz Martínez

**Hospital Universitario de la Princesa:** Yohana Gil Giraldo, Martín Giorgi, Carmen Sánchez, Ana Sánchez Horrillo, Pablo Ruano Suárez, Antonio Fernández Perpén, Andrés Fernández Ramos, Laura Salanova Villanueva, Alejandro Cortiñas, Pablo A. Díez Arias, Alicia Cabrera Cárdenas, Antonio de Santos, Almudena Núñez, Guillermina Barril Cuadrado, Raquel Repollet

**Hospital Universitario Marqués de Valdecilla:** Rosalía Valero San Cecilio, Celestino Piñera Haces, María Kislikova, Emilio Rodrigo

**Hospital Vell D’Hebrón:** Francesc Moreso

**Hospital Fundación Jiménez Diaz:** Emilio Gonzalez-Parra, Catalina Martin-Cleary, Jinny Sánchez-Rodríguez y Ana Ramos-Verde

**Hospital Universitario de Donostia:** María Teresa Rodrigo De Tomas, Beatriz Aizcue Prieto, Carmen Toyos Y José Molina Del Rio, Adriana Restrepo Acosta, Amagoia Celayeta Zamacona

**Hospital General de Alicante:** Francisco Javier Pérez Contreras, Dioné González Ferri, Eduardo Muñoz de Bustillo Llorente

**Clínica Universidad de Navarra:** Nuria García-Fernández, Paloma Leticia Martín Moreno, Noelia Ania González, Ana Sabalza Ortiz, María Nieves Bastida Ibarra

**Hospital Universitario Fundación de Alcorcón:** Ana M. Tato Ríbera, Eduardo Gallego Valcarce, Enrique Gruss Vergara

**Hospital Universitario Puerta de Hierro:** María Rosario Llópez Carratalá, Leyre María Martín Rodríguez, Marisa Serrano Salazar, Begoña Bravo Prieto, José María Portolés Pérez

**Hospital de Galdakao:** Mª Isabel Jimeno Martin, Saioa Bilbao Ortega, Mª Isabel Gallardo Ruiz, Ainhoa Hernandez Rubio, Paula García Ledesma, Alvaro Goyoaga Alvarez
REFERENCES

1. ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant 2021; 36: 87–94

2. Williamson EJ, Walker AJ, Bhaskaran K et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430–436

3. Kato S, Chimielewski M, Honda H et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526–1533

4. Toapanta N, Bestard O, Soler MJ. SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response? Nephrol Dial Transplant 2021; 36: 1950–1954

5. Kamar N, Abravanel F, Marion O et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021; 385: 661–662

6. Grupper A, Sharon N, Finn T et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol 2016; 11: 1037–1042

7. Rodríguez-Espinosa D, Broseta JJ, Maduell F. et al. Neutralization of SARS-CoV-2 variants of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients. Kidney Int 2021; 100: 476–477

8. Crespo M, Barrilado-Jackson A, Padilla E et al. Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring. Am J Transplant 2021 (in press)

9. Carr E, Kronbichler A, Graham-Brown M. et al. Systematic review of early immune response to SARS-CoV-2 vaccination among patients with chronic kidney disease. Kidney Int 2021; 100: 476–477

10. Bates TA, Leier HC, Lyski ZL et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nat Commun 2021; 12: 5135

11. Grupper A, Rabinowich L, Schwartz D et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021; 21: 2719–2726

12. Boyarsky BJ, Werbel WA, Avery RK et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021; 325: 2020–2024

13. Rozen-Zvi B, Yahav D, Agur T et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect 2021; 27: 1173.e1–1173.e4

14. Cai C, Peng Y, Shen E et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther 2021; 29: 2794–2801

15. Bergwerk M, Gonen T, Lustig Y et al. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021; 385: 1474–1484

16. Stumpf J, Siepmann T, Lindner T et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur 2021; 9: 100178

17. Vassilaki N, Gargalionis AN, Bleta A et al. Impact of age and sex on antibody response following the second dose of COVID-19 BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms 2021; 9: 1725
18. Van Praet J, Reynders M, De Bacquer D et al. Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: a multicenter observational study. *J Am Soc Nephrol* 2021 (in press)

19. Smogorzewski M, Massry SG. Defects in B-cell function and metabolism in uremia: role of parathyroid hormone. *Kidney Int* 2001; 59: S186–S189

20. Horton DB, Barrett ES, Roy J et al. Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. *J Infect Dis* 2021; 224: 1345–1356

21. Zollner A, Watschinger C, Rössler A et al. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. *EBioMedicine* 2021; 70: 103539

22. Jeet Kaur R, Dutta S, Charan J et al. Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. *Int J Gen Med* 2021; 14: 3909–3927

23. Broseta JJ, Rodriguez-Espinosa D, Soruco E et al. Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients. *Nephrol Dial Transplant* 2021; 36: 1754–1755

Received: 11.9.2021; Editorial decision: 17.10.2021